Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cohera Medical Inc.

This article was originally published in Start Up

Executive Summary

The lead product from Cohera Medical platform technology is a sprayable adhesive strong enough to hold tissue layers together following surgery. TissuGlu is an absorbable, urethane adhesive that is non-toxic for use inside the body. The initial indication will be plastic surgery, with an emphasis on abdominoplasty (tummy tuck). For such a procedure, the product is sprayed in between two flaps of tissue for reattachment, thus preventing fluid buildup that would otherwise occur between unattached layers of tissue and require cumbersome post-surgical drains with their associated complications.

You may also be interested in...



Start-Up Previews (09/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.

Start-Up Previews (09/2008)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.

Advanced Wound Care: The Device Industry's New Billion Dollar Product Market

For some time now, investors have hated wound care. They've been scarred by past failures, most famously, the simultaneous bankruptcies in 2002 of Advanced Tissue Sciences and Organogenesis, two tissue-engineering companies targeting chronic wounds. "Show me one success," VCs tell start-ups seeking funding. Well, now there is one. Kinetic Concepts is pulling in a billion dollars in revenues from a single product in the advanced wound care market. Is it time for VCs to love advanced wound care? Five new device start-ups hope so. Three are developing therapeutic devices for chronic wounds and two are beginning in acute wound care, an emerging surgical market. (This article also appeared as "Wound Care: Medtech's New Billion Dollar Product Market," Medtech Insight November/December 2007)

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037570

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel